Submit

Login Login

Register Register

Home / Journals / BIOCELL / Online First / doi:10.32604/biocell.2024.048737
Journal Menu
Special lssues
Table of Content

All issues

Online First

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

SAIB Annual Meetings

Open Access

ARTICLE

CARD11 serves as a therapeutic biomarker for the drug therapies of ccRCC

KAIWEN TIAN#, HANZHONG CHEN#, QIANQIAN WANG, FENGLIAN JIANG, CHUNXIANG FENG, TENG LI, XIAOYONG PU, YANLIN TANG*, JIUMIN LIU*
Department of Urology, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, China
* Corresponding Author: YANLIN TANG. Email: email; JIUMIN LIU. Email: email
(This article belongs to the Special Issue: Frontiers in cancer: tumor microenvironment)

BIOCELL https://doi.org/10.32604/biocell.2024.048737

Received 16 December 2023; Accepted 29 January 2024; Published online 19 March 2024

Abstract

Background: The incidence of clear cell renal cell carcinoma (ccRCC) is globally high; however, despite the introduction of innovative drug therapies, there remains a lack of effective biomarkers for evaluating treatment response. Recently, Caspase recruiting domain-containing protein 11 (CARD11) has garnered attention due to its significant association with tumor development and the immune system. Methods: The expression of CARD11 mRNA and protein in ccRCC were analyzed by public database and immunohistochemistry. The focus of this study is on the epigenomic modifications of CARD11, its expression of ccRCC immunophenotype, and its correlation with response to immunotherapy and targeted therapy. Furthermore, to investigate the mechanism of this molecule’s influence on different biological behaviors of cells, cell tests in vitro have been conducted to observe the impact of its expression level. Results: CARD11 expression was upregulated which may be mainly modified by body methylation and was correlated with poor prognosis in ccRCC. In the tumor microenvironment of ccRCC, CARD11 expression was positively correlated with increased T lymphocyte infiltration and increased expression of inhibitory immune checkpoints. Moreover, ccRCC patients with high CARD11 expression had a better response to immunotherapy and targeted therapy. The knockdown of CARD11 ultimately suppressed the proliferation, migration, and invasion capabilities of ccRCC cells while simultaneously enhancing tumor cell apoptosis. Conclusion: We identified CARD11 as a novel therapeutic biomarker for immunotherapy and targeted therapy in ccRCC.

Graphical Abstract

CARD11 serves as a therapeutic biomarker for the drug therapies of ccRCC

Keywords

Clear cell renal cell carcinoma; Tumor microenvironment; CARD11; Immune checkpoint inhibitor; Tyrosine kinase inhibitor

  • 270

    View

  • 67

    Download

  • 0

    Like

Related articles
Copyright© 2024 Tech Science Press
© 1997-2024 TSP (Henderson, USA) unless otherwise stated

Share Link